Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo

European Journal of Pharmacology

Volumn 764, Issue , 2015, Pages 508-519

  Nidhyanandan, Saranya ^a,c   Boreddy, Thippeswamy S ^b   Chandrasekhar, Kothapalli B ^c   Reddy, Neetinkumar D ^a   Kulkarni, Nagaraj M ^a   Narayanan, Shridhar ^d  

^a Orchid Chemicals and Pharmaceuticals Ltd   (India)

^b SHAQRA UNIVERSITY   (Saudi Arabia)

^c JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^d SIR M VISVESVARAYA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Apoptosis; HDAC; MS 275; PDE; Pentoxifylline; Xenograft

Indexed keywords

ENTINOSTAT; HISTONE DEACETYLASE; PENTOXIFYLLINE; PHOSPHODIESTERASE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CELL CYCLE REGULATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME REGULATION; HCT 116 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MCF 7 CELL LINE; MDA MB 231 CELL LINE; MONOTHERAPY; MOUSE; NONHUMAN; PC3 CELL LINE; PRIORITY JOURNAL; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BREAST NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; FEMALE; HCT116 CELL LINE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SCID MOUSE; TUMOR VOLUME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; BREAST NEOPLASMS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MCF-7 CELLS; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PYRIDINES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938373528     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.07.048     Document Type: Article

References (30)

1. M. Barancik, V. Bohacova, L. Gibalova, J. Sedlak, Z. Sulova, and A. Breier Potentiation of anticancer drugs: effects of Pentoxifylline on neoplastic cells Int. J. Mol. Sci. 13 2012 369 382
2. M. Bots, and R.W. Johnstone Rationale combinations using HDAC inhibitors Clin. Cancer Res. 15 2009 3970 3977
3. A. Bravo-Cuellar, P.C. Ortiz-Lazareno, J.M. Lerma-Diaz, J.R. Dominguez-Rodriguez, L.F. Jave-Suarez, A. Aguilar-Lemarroy, S. Toro-Arreola, R. Celis-Carrillo, J.E. Sahagun-Flores, J.E. Alba-Garcia, and G. Hernandez-Flores Sensitization of cervix cancer cells to Adriamycin by Pentoxifylline induces an increase in apoptosis and decrease senescence Mol. Cancer 9 2010 114
4. M.Y. Chen, W.S.L. Liao, Z. Lu, W.G. Bornmann, V. Hennessey, M.N. Washington, G.L. Rosner, Y. Yu, A.A. Ahmed, and R.C. Bast Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest and autophagy Cancer 117 2011 4424 4438
5. Y. Dai, C. Yu, V. Singh, and et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01to induce mitochondrial dysfunction and apoptosis in human leukemia cells Cancer Res. 61 2001 5106 5115
6. H. Dong, C. Zitt, C. Auriga, A. Hatzelmann, and P.M. Epstein Inhibition of PDE3, PDE4 and PDE7 potentiates glucocorticoid-induced apoptosis and overcomes glucocorticoid resistance in CEM T leukemic cells Biochem. Pharmacol. 79 2010 321 329
7. H. Duan, C.A. Heckman, and L.M. Boxer Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas Mol. Cell. Biol. 25 2005 1608 1619
8. P.N. Goel, and R.P. Gude Delineating the anti-metastatic potential of pentoxifylline in combination with liposomal doxorubicin against breast cancer cells Biomed. Pharmacother. 68 2014 191 200
9. G. Hernandez-Flores, P.C. Ortiz-Lazareno, J.M. Lerma-Diaz, J.R. Dominguez-Rodriguez, L.F. Jave-Suarez, A.C. Aguilar-Lemarroy, R. Celis-Carrillo, S. Toro-Arreola, Y.C. Castellanos-Esparza, and A. Bravo-Cuellar Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence BMC Cancer 11 2011 483
10. L. Hirsh, A. Dantes, B.S. Suh, and et al. Phosphodiesterase inhibitors as anti-cancer drugs Biochem. Pharmacol. 68 2004 981 988
11. Y. Jiang, Y. Wang, Z. Su, L. Yang, W. Guo, W. Liu, and J. Zuo Synergistic induction of apoptosis in hela cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor saha Mol. Med. Rep. 3 2010 613 619
12. Y. Kato, K. Yoshimura, T. Shin, H. Verheul, H. Hammers, and et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma Clin. Cancer Res. 13 2007 4538 4546
13. N. Khan, M. Jeffers, S. Kumar, C. Hackett, F. Boldog, N. Khramtsov, X. Qian, E. Mills, S.C. Berghs, N. Carey, P.W. Finn, L.S. Collins, A. Tumber, J.W. Ritchie, P.B. Jensen, and H.S. Lichenstein Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors Biochem. J. 409 2008 581 589
14. A. Khandelwal, L.K. Gediya, and V.C.O. Njar MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours Br. J. Cancer 98 2008 1234 1243
15. P.J. Kraft, Y. Qiu, D.H. Johnson, S. Bhattacharjee, and et al. Comparison of PDE expression profiles of human prostate and prostate cancer cell lines and the effect of PDE inhibitors on cell proliferation FASEB J. 20 2006 A1131
16. C.A. Krusche, and P. Wulfing Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis Breast Cancer Res. Treat. 90 2005 15 23
17. S. Li, M. Ciesielski, S. Ramakrishnan, K.M. Miles, L. Ellis, P. Sotomayor, P. Shrikant, R. Fenstermaker, and R. Pili mail Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models PLoS One 7 2012 1 14
18. X. Li, and W. Xu HDAC1/3 dual selective inhibitors-new therapeutic agents for the potential treatment of cancer Drug Discov. Ther. 8 2014 225 228
19. S.C. Maggio, R.R. Rosato, L.B. Kramer, Y. Dai, M. Rahmani, D.S. Paik, A.C. Czarnik, S.G. Payne, S. Spiegel, and S. Grant The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells Cancer Res. 64 2004 2590 2600
20. D.G. McEwan, V.G. Brunton, G.S. Baillie, and et al. Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase Cancer Res. 67 2007 5248 5257
21. K. Murata, M. Kameyama, F. Fukui, and et al. Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility Clin. Exp. Metastasis 17 1999 525 530
22. I. Postiglione, A. Chiaviello, and G. Palumbo Enhancing photodynamyc therapy efficacy by combination therapy: dated current and oncoming strategies Cancers 3 2011 2597 2629
23. D.Z. Qian, X. Wang, S.K. Kachhap, and et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogen-esis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 Cancer Res. 64 2004 6626 6634
24. G.J. Sabnis, O.G. Goloubeva, A.A. Kazi, P. Shah, and A.H. Brodie HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2 Mol. Cancer Ther. 12 2013 2804 2816
25. T. Suzuki, A. Inoue, Y. Miki, T. Moriya, J. Akahira, T. Ishida, H. Hirakawa, Y. Yamaguchi, S. Hayashi, and H. Sasano Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor Endocr. Relat. Cancer 14 2007 279 292
26. V. Vichai, and K. Kirtikara Sulforhodamine B colorimetric assay for cytotoxicity screening Nat. Protoc. 3 2006 1112 1116
27. J.A. Vrana, Z. Wang, A.S. Rao, and et al. Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1 Leukemia 13 1999 1046 1055
28. R.M. Wallis, J.D. Corbin, S.H. Francis, and P. Ellis Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic ring in vitro Am. J. Cardiol. 83 5A 1999 3C 12C
29. D. Waltregny, B. North, F. Van Mellaert, J. de Leval, E. Verdin, and V. Castronovo Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDACprofiles between epithelial and stromal cells Eur. J. Histochem. 48 2004 273 290
30. N. Wang, L. Chen, L. Zhang, R. Jiang, L. Chen, and Y. Shen Inhibitory effect of suberoylanilide hydroxamic acid on angiogenesis and its molecular mechanism Chin. J. Cell. Mol. Immunol. 30 2014 266 269